arrow
S

Satoshi Kubo

University of Occupational and Environmental Health
H指数:38
被引数:7,044

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effectiveness of biological disease-modifying antirheumatic drugs in progressive pulmonary fibrosis associated with rheumatoid arthritis

类风湿关节炎相关进行性肺纤维化中生物制剂改善病情抗风湿药的有效性

2026-08-200
PRE
Effectiveness and safety of sarilumab in polymyalgia rheumatica: A retrospective study of the FIRST registry

沙利鲁单抗在风湿性多肌痛中的有效性与安全性:FIRST登记研究的回顾性研究

2026-01-010
PRE
Impact of glucocorticoid tapering speed on renal outcomes in proliferative lupus nephritis: a multicentre retrospective study

糖皮质激素减量速度对增生性狼疮肾炎肾功能结局的影响:一项多中心回顾性研究

2025-05-130
PRE
Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry

FIRST注册研究中对对一线b/tsDMARDs无应答的类风湿关节炎患者有效的二线b/tsDMARDs

2025-03-011
OA
AMBRA1 controls the translation of immune- specific genes in T lymphocytes

AMBRA1控制T淋巴细胞中免疫特异性基因的翻译

2024-10-220
OAAI
Efficacy and safety of lenvatinib in patients with chemotherapy-naive advanced or recurrent thymic carcinoma: A multicenter retrospective study

仑伐替尼在化疗初治的晚期或复发性胸腺癌患者中的有效性和安全性:一项多中心回顾性研究

2024-09-010
PRE
SAFETY AND EFFICACY OF ANIFROLUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) WITH MINOR FLARES AFTER ACHIEVING THE LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) IN REAL-WORLD CLINICAL PRACTICE:LOOPS REGISTRY

系统性红斑狼疮(SLE)患者达到狼疮低疾病活动状态(LLDAS)后,在真实世界临床实践中,出现轻微复发时anifrolumab的安全性与有效性:LOOPS注册研究

2024-06-010
PRE